Literature DB >> 19447057

Pharmacophore and docking-based combined in-silico study of KDR inhibitors.

F A Pasha1, M Muddassar, M M Neaz, Seung Joo Cho.   

Abstract

The growth and metastasis of solid tumors is dependent on angiogenesis. The vascular endothelial growth factor (VEGF) and its cell surface receptor in human KDR (kinase domain containing receptor or VEGFR-2) have particular interest because of their importance in angiogenesis. The development of novel inhibitors of VEGFR-2 would be helpful to check the growth of tumors. Quantitative structure activity relationship (QSAR) analyses used to understand the structural factors affecting inhibitory potency of thiazole-substituted pyrazolone derivatives. Several pharmacophore-based models indicated the importance of steric, hydrophobic and hydrogen bond acceptor groups to inhibitory activity. The comparative molecular field analyses (CoMFA) and comparative molecular similarity indices analyses (CoMSIA) based 3D-QSAR models were derived using pharmacophore-based alignment. Both CoMFA (q(2)=0.70, r(2)=0.97 and r(predictive)(2)=0.61) and CoMSIA (q(2)=0.54, r(2)=0.82 and r(predictive)(2)=0.66) gave reasonable results. The molecular docking (receptor-guided technique) with a recently reported receptor structure (PDB=1YWN) were performed. The docked alignment was subsequently used for 3D-QSAR (CoMFA; q(2)=0.56, r(2)=0.97, r(predictive)(2)=0.82, CoMSIA; q(2)=0.58 r(2)=0.91, r(predictive)(2)=0.69). The overall both studies were indicated, steric, electrostatic and hydrogen bond acceptor effects contribute to the inhibitory activity. CoMFA and CoMSIA models suggested that a positive bulk with hydrophobic effect is desirable around position 4 and 5 and hydrogen bond acceptor groups around pyrazolones ring will be helpful.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447057     DOI: 10.1016/j.jmgm.2009.04.006

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  7 in total

1.  Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches.

Authors:  Rino Ragno; Flavio Ballante; Adele Pirolli; Richard B Wickersham; Alexandros Patsilinakos; Stéphanie Hesse; Enrico Perspicace; Gilbert Kirsch
Journal:  J Comput Aided Mol Des       Date:  2015-07-21       Impact factor: 3.686

2.  Identification and characterization of agnuside, a natural proangiogenic small molecule.

Authors:  Piyush Pillarisetti; Kenneth A Myers
Journal:  Eur J Med Chem       Date:  2018-10-05       Impact factor: 6.514

3.  Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.

Authors:  Farhan Ahmad Pasha; Mohammad Morshed Neaz
Journal:  J Mol Model       Date:  2012-10-20       Impact factor: 1.810

4.  Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.

Authors:  Sudhan Debnath; Tanusree Debnath; Samhita Bhaumik; Swapan Majumdar; Arunasree M Kalle; Vema Aparna
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

5.  Highly efficient catalyst-free domino conjugate addition, decarboxylation and esterification/amidation of coumarin carboxylic acid/esters with pyrazolones: a green chemistry approach.

Authors:  Shanta Raj Lakshmi; Vipin Singh; L Raju Chowhan
Journal:  RSC Adv       Date:  2020-04-06       Impact factor: 4.036

6.  (Z)-1-(2-Chloro-phen-yl)-3-methyl-4-[2-(4-nitro-phen-yl)hydrazin-1-yl-idene]-1H-pyrazol-5(4H)-one.

Authors:  Carlos Bustos; Andrés Escobar-Fuentealba; Luis Alvarez-Thon; Rodrigo Faundez-Gutierrez; Maria Teresa Garland
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-07-07

7.  The biological activity of new thieno[2,3-c]pyrazole compounds as anti-oxidants against toxicity of 4-nonylphenol in Clarias gariepinus.

Authors:  Alaa El-Din H Sayed; Remon M Zaki; Adel M Kamal El-Dean; Abdullah Y Abdulrazzaq
Journal:  Toxicol Rep       Date:  2015-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.